Advertisement
Advertisement
IKT
Inhibikase Therapeutics, Inc. Common Stock
1.88
USDSponsored
0.00
+0.27%
Jun 25, 12:38 UTC -4
Open
IKT Earnings Reports
Positive Surprise Ratio
IKT beat 11 of 20 last estimates.
55%
Next Report
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.10
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
--
/-9.09%
Inhibikase Therapeutics, Inc. Common Stock earnings per share and revenue
On May 12, 2026, IKT reported earnings of -0.10 USD per share (EPS) for Q1 26, beating the estimate of -0.10 USD, resulting in a 8.59% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.04% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -0.10 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
What were Inhibikase Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Inhibikase Therapeutics, Inc. Common Stock reported EPS of -$0.10, beating estimates by 8.59%, and revenue of $0.00, 0% as expectations.
How did the market react to Inhibikase Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -1.04%, changed from $1.92 before the earnings release to $1.90 the day after.
When is Inhibikase Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Inhibikase Therapeutics, Inc. Common Stock's next earnings report?
Based on 4
analysts, Inhibikase Therapeutics, Inc. Common Stock is expected to report EPS of -$0.10 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement